Eli Lilly touts long-term data on Omvoh for ulcerative colitis, Crohn’s
by
Contributor since / Followers
Contributor since / Followers
2 months ago
JHVEPhoto
- Eli Lilly (NYSE:LLY) said that data from two phase 3 studies found that patients treated with Omvoh (mirikizumab) saw long-term remission of ulcerative colitis or Crohn’s disease.
- Results from the LUCENT-3 study found that after up to three years of treatment with the monoclonal antibody, 81% of UC patients maintained long-term clinical remission. In addition, 82% achieved long-term endoscopic remission and there was a sustained clinically meaningful improvement in symptom score reduction of -4.72 for bowel urgency.
- In the VIVID-2 trial, after up to five years of treatment, 87% of Crohn’s patients were in clinical remission as measured by Crohn’s Disease Activity Index. Also, 54% were in endoscopic remission.
- In the U.S., Omvoh is only approved for UC.